Diamandis joins Radicle Science as the healthtech company accelerates growth with industry veteran Sheldon Borkin PhD as CTO, the launch of a first of its kind real-world sleep study, and updates on significant milestones this year
Radicle Science, a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021.
Notably, Peter H. Diamandis, MD joined as Chair of the Radicle Science Advisory Board in October 2021. Recently named by Fortune as one of the "World's 50 Greatest Leaders," Diamandis is the founder and Executive Chair of the XPRIZE Foundation, which leads the world in running large-scale competitions to develop technologies that benefit humanity. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies.
"The co-founders of Radicle Science, Pelin and Jeff, along with the team who's joined their movement, are brilliant, passionate and inspiring. Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions," said Diamandis. "Radicle Science has the potential to help dematerialize, demonetize and democratize clinical trials, and unlock a future of meaningful and abundant health products directly accessible by all."
Radicle Science also announced a new CTO, Sheldon Borkin, PhD, who joined in September 2021. Borkin has been a technical and business leader at numerous start-ups and contributed his expertise to multiple IPOs. While at WebMD from startup through IPO to $1B/yr revenue, he held multiple senior technical and leadership roles, including Chief Security Officer.
"We've experienced extraordinary growth across all dimensions of our business over the past year, including the recent additions to our trailblazing team. We couldn't be more excited to have Peter Diamandis as the new Chairman of our Advisory Board and Sheldon Borkin as our new CTO. Peter is an exceptional global leader with a bold trans-disciplinary approach that will help Radicle achieve our audacious vision," said Jeff Chen, MD/MBA, Co-founder and CEO of Radicle Science. "And Sheldon's wealth of experience in analytics, agile software development, and healthtech will be critical as we continue to scale rapidly."
The two new leadership additions follow the news of the newly formed alliance between Radicle Science and Open Book Extracts (OBX), a leading ingredient manufacturer and product developer of cannabinoid-enabled products, to advance the development of market-leading, scientifically validated CBD and other cannabinoid products, and the launch of multiple rigorous scientific studies on cannabinoid effectiveness.
This week, Radicle Science also marks the launch of Radicle Real World Sleep, a series of first of its kind real-world evidence (RWE) studies focused exclusively on the effectiveness of cannabinoid products on sleep. These four-week, randomized, controlled trials (RCT) of orally ingestible cannabinoid products will generate RWE insights in areas including user behavior and characteristics, health status, dosing, consumption patterns, effectiveness for various health outcomes, onset and duration of effect, side effects, and possible predictors/modifiers of treatment response. Brands participating in the studies include Cannafloria Wellness, CÜRE CBD Wellness, Mendi, RealSleep, Straight Hemp, Our Treaty, Trokie, and Vitaldiol.
Other groundbreaking studies from Radicle Science in 2021 include:
- CBD and Women's Health, the first CBD RCT focusing specifically on women, conducted in partnership with Rae Wellness, across 1,350 participants;
- Radicle ACES, the largest CBD RCT to date and the first multi-brand, Institutional Review Board (IRB) approved study on CBD effectiveness across well-being, quality of life, pain, sleep disturbance, and anxiety, conducted in partnership with 13 leading CBD brands, across nearly 3,000 participants;
- Radicle Discovery, one of history's first RCTs on rare cannabinoids, studying various formulations across 1800 participants.
The results of the Rae Wellness women's health study are available here, while the findings from Radicle ACES will be released later this year. Radicle Real World Sleep results will be announced in early 2022.
"We have achieved a lot of ‘firsts' this year for the cannabinoid industry, notably the completion of the Rae Wellness study, the first study ever on the effectiveness of CBD for women's health, and the Radicle ACES study, the largest CBD RCT to date. These studies are providing the statistical power to start generating insights on what types of products, used in what manner, may most effectively address which need states," said Pelin Thorogood, Co-founder and Executive Chair of Radicle Science. "We are digging deeper into other use cases for CBD as well as other cannabinoids, exemplified by our upcoming Radicle Real World Sleep study and the Radicle Discovery on rare cannabinoids. The CBD industry and consumers alike have been eager for more meaningful research. Our mission is to disrupt the clinical trial model to apply rigorous scientific research for consumer health product validation at scale. What we've accomplished thus far is only the beginning!"
Co-founders Jeff Chen and Pelin Thorogood will also be speaking to business leaders from the cannabinoid industry at the Trailblazers semi-annual event in Ojai in October, on how Radically Rapid Research can enable better trust, business decisions, and health outcomes across the industry.
About Radicle Science
Radicle Science is a transformative healthtech B-corp offering the first ever path to consumer health product validation at scale. Radicle Science disrupts the traditional clinical trial model by combining the reach of a market research company, the scientific rigor of a research university, and the agility of a tech company. Operating at the intersection of big data, digital health, and natural products, Radicle Science leverages a proprietary data analytics platform and a virtual, direct-to-consumer (D2C) model to deliver objective health outcome data across diverse populations and conditions. Our Radicle Vision is a future where affordable, accessible, consumer health products are trusted by patients, recommended by healthcare providers, reimbursed by insurance, and used as widely as pharmaceutical drugs. To learn more, please visit www.radiclescience.com and follow their LinkedIn page and Twitter page.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.